Jacqueline E Tate1, Fidele Ngabo2, Philippe Donnen2, Maurice Gatera3, Jeannine Uwimana4, Celse Rugambwa5, Jason M Mwenda6, Umesh D Parashar1. 1. Centers for Disease Control and Prevention, Atlanta, Georgia. 2. Universite Libre de Bruxelles, Ecole de Santé Publique, Brussels, Belgium. 3. Rwanda Biomedical Center. 4. University Teaching Hospital. 5. World Health Organization, Rwanda Office, Kigali. 6. World Health Organization, Regional Office for Africa, Brazzaville, Republic of Congo.
Abstract
BACKGROUND: Rotavirus vaccine efficacy is lower in low-income countries than in high-income countries. Rwanda was one of the first low-income countries in sub-Saharan Africa to introduce rotavirus vaccine into its national immunization program. We sought to evaluate rotavirus vaccine effectiveness (VE) in this setting. METHODS: VE was assessed using a case-control design. Cases and test-negative controls were children who presented with a diarrheal illness to 1 of 8 sentinel district hospitals and 10 associated health centers and had a stool specimen that tested positive (cases) or negative (controls) for rotavirus by enzyme immunoassay. Due to high vaccine coverage almost immediately after vaccine introduction, the analysis was restricted to children 7-18 weeks of age at time of rotavirus vaccine introduction. VE was calculated as (1 - odds ratio) × 100, where the odds ratio was the adjusted odds ratio for the rotavirus vaccination rate among case-patients compared with controls. RESULTS: Forty-eight rotavirus-positive and 152 rotavirus-negative children were enrolled. Rotavirus-positive children were significantly less likely to have received rotavirus vaccine (33/44 [73%] unvaccinated) compared with rotavirus-negative children (81/136 [59%] unvaccinated) (P= .002). A full 3-dose series was 75% (95% confidence interval [CI], 31%-91%) effective against rotavirus gastroenteritis requiring hospitalization or a health center visit and was 65% (95% CI, -80% to 93%) in children 6-11 months of age and 81% (95% CI, 25%-95%) in children ≥12 months of age. CONCLUSIONS: Rotavirus vaccine is effective in preventing rotavirus disease in Rwandan children who began their rotavirus vaccine series from 7 to 18 weeks of age. Protection from vaccination was sustained after the first year of life. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Rotavirus vaccine efficacy is lower in low-income countries than in high-income countries. Rwanda was one of the first low-income countries in sub-Saharan Africa to introduce rotavirus vaccine into its national immunization program. We sought to evaluate rotavirus vaccine effectiveness (VE) in this setting. METHODS: VE was assessed using a case-control design. Cases and test-negative controls were children who presented with a diarrheal illness to 1 of 8 sentinel district hospitals and 10 associated health centers and had a stool specimen that tested positive (cases) or negative (controls) for rotavirus by enzyme immunoassay. Due to high vaccine coverage almost immediately after vaccine introduction, the analysis was restricted to children 7-18 weeks of age at time of rotavirus vaccine introduction. VE was calculated as (1 - odds ratio) × 100, where the odds ratio was the adjusted odds ratio for the rotavirus vaccination rate among case-patients compared with controls. RESULTS: Forty-eight rotavirus-positive and 152 rotavirus-negative children were enrolled. Rotavirus-positive children were significantly less likely to have received rotavirus vaccine (33/44 [73%] unvaccinated) compared with rotavirus-negative children (81/136 [59%] unvaccinated) (P= .002). A full 3-dose series was 75% (95% confidence interval [CI], 31%-91%) effective against rotavirus gastroenteritis requiring hospitalization or a health center visit and was 65% (95% CI, -80% to 93%) in children 6-11 months of age and 81% (95% CI, 25%-95%) in children ≥12 months of age. CONCLUSIONS: Rotavirus vaccine is effective in preventing rotavirus disease in Rwandan children who began their rotavirus vaccine series from 7 to 18 weeks of age. Protection from vaccination was sustained after the first year of life. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Martin M Nyaga; Yi Tan; Mapaseka L Seheri; Rebecca A Halpin; Asmik Akopov; Karla M Stucker; Nadia B Fedorova; Susmita Shrivastava; A Duncan Steele; Jason M Mwenda; Brett E Pickett; Suman R Das; M Jeffrey Mphahlele Journal: Infect Genet Evol Date: 2018-05-18 Impact factor: 3.342
Authors: Shu Zhu; Siyuan Ding; Penghua Wang; Zheng Wei; Wen Pan; Noah W Palm; Yi Yang; Hua Yu; Hua-Bing Li; Geng Wang; Xuqiu Lei; Marcel R de Zoete; Jun Zhao; Yunjiang Zheng; Haiwei Chen; Yujiao Zhao; Kellie A Jurado; Ningguo Feng; Liang Shan; Yuval Kluger; Jun Lu; Clara Abraham; Erol Fikrig; Harry B Greenberg; Richard A Flavell Journal: Nature Date: 2017-06-21 Impact factor: 49.962
Authors: Lauren M Schwartz; M Elizabeth Halloran; Ali Rowhani-Rahbar; Kathleen M Neuzil; John C Victor Journal: Vaccine Date: 2016-11-18 Impact factor: 3.641